Provided by Tiger Fintech (Singapore) Pte. Ltd.

Processa Pharmaceuticals, Inc.

0.2200
-0.0340-13.39%
Post-market: 0.23190.0119+5.41%19:59 EDT
Volume:1.29M
Turnover:302.09K
Market Cap:1.16M
PE:-0.06
High:0.2599
Open:0.2440
Low:0.1500
Close:0.2540
Loading ...

Company Profile

Company Name:
Processa Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
10
Office Location:
7380 Coca Cola Drive,Suite 106,Hanover,Maryland,United States
Zip Code:
21076
Fax:
443 288 4420
Introduction:
Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.

Directors

Name
Position
David Young
President and Chief Executive Officer and Director
Justin Yorke
Chairman of the Board
Geraldine Pannu
Director
James Neal
Director
Khoso Baluch
Director
Virgil Thompson
Director

Shareholders

Name
Position
David Young
President and Chief Executive Officer and Director
James Stanker
Chief Financial Officer
Michael Floyd
Chief Operations Officer
Patrick Lin
Chief Business and Strategy Officer
Sian Bigora
Chief Development Officer
Wendy Guy
Chief Administrative Officer